Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Adagio Therapeutics, Inc. (ADGI : NSDQ)
 
 • Company Description   
Adagio Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Adagio Therapeutics Inc. is based in WALTHAM, Mass.

Number of Employees: 103

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.97 Daily Weekly Monthly
20 Day Moving Average: 1,218,345 shares
Shares Outstanding: 109.71 (millions)
Market Capitalization: $325.85 (millions)
Beta:
52 Week High: $59.50
52 Week Low: $2.46
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.34% 12.26%
12 Week -53.15% -48.50%
Year To Date -59.09% -50.01%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1601 TRAPELO ROAD SUITE 178
-
WALTHAM,MA 02451
USA
ph: 781-819-0080
fax: -
investors@adagiotx.com http://adagiotx.com
 
 • General Corporate Information   
Officers
David Hering - Interim Chief Executive Officer and Chief Operatin
Rene Russo - Co-Founder; Director and Chair of the Board
Jane Pritchett Henderson - Chief Financial Officer and Chief Business Officer
Terrance McGuire - Director
Ajay Royan - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00534A102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/19/22
Share - Related Items
Shares Outstanding: 109.71
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $325.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.14 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/19/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.71
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -76.69
12/31/21 - -96.17
09/30/21 - -
ROA
03/31/22 - -51.09
12/31/21 - -50.42
09/30/21 - -
Current Ratio
03/31/22 - 5.80
12/31/21 - 9.94
09/30/21 - 12.82
Quick Ratio
03/31/22 - -
12/31/21 - 9.94
09/30/21 - 12.82
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.19
12/31/21 - 5.02
09/30/21 - 5.69
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©